Recipharm AB operates as a pharmaceutical contract development and manufacturing company. Its dosage forms include solid dose, steriles, semi solids, beta-lactams, hormones, dry powder inhalers, granulates, and powders. The company provides pharmaceutical development services, such as formulation development, clinical supplies, analytical development, stability studies, packaging development and selection, and raw material selection; and manufacturing services. It also offers EU gateway release and testing, regulatory, stability studies, and customized services. Recipharm AB was founded in 1995 and is based in Haninge, Sweden. It has manufacturing facilities in Sweden, France, and the United Kingdom.

Type
Public
HQ
Stockholm, SE
Size (employees)
2,838 (est)+8%
Recipharm is headquartered in Stockholm, SE
Report incorrect company information

Key People/Management at Recipharm

Thomas Eldered

Thomas Eldered

Chief Executive Officer
Kenth Berg

Kenth Berg

Vice President, Business Management
Kjell Johansson

Kjell Johansson

President, Manufacturing Services Europe
Karl Lindstrom

Karl Lindstrom

Interim Chief Financial Officer
Mark Quick

Mark Quick

Executive Vice President, Corporate Development
Jonas Lejontand

Jonas Lejontand

Vice President, Human Resources
Show more

Recipharm Office Locations

Recipharm has an office in Stockholm
Stockholm, SE (HQ)
Lagervagen 7
Show all (1)
Report incorrect company information

Recipharm Financials and Metrics

Recipharm Financials

Recipharm's revenue was reported to be kr3.55 b in FY, 2015 which is a 31.9% increase from the previous period.
SEK

Revenue (FY, 2015)

3.5 b

Revenue growth (FY, 2014 - FY, 2015), %

31.9%

Gross profit (FY, 2015)

2.6 b

Gross profit margin (FY, 2015), %

73%

Net income (FY, 2015)

215.1 m

EBITDA (FY, 2015)

509.8 m

EBIT (FY, 2015)

274.2 m

Market capitalization (31-Oct-2017)

6.4 b

Closing share price (31-Oct-2017)

100.3

Cash (31-Dec-2015)

534.2 m

EV

7.6 b
Recipharm's current market capitalization is kr6.4 b.
SEKFY, 2014FY, 2015

Revenue

2.7 b3.5 b

Revenue growth, %

32%

Cost of goods sold

703.9 m958.8 m

Gross profit

2 b2.6 b
sekY, 2014Y, 2015

Cash

404.5 m534.2 m

Total Assets

5.4 b5.7 b

Total Debt

1.6 b1.7 b

Total Liabilities

5.4 b3 b
SEKFY, 2014FY, 2015

Cash From Operating Activities

254.2 m428.8 m
SEKY, 2015

EV/EBITDA

14.9 x

EV/EBIT

27.7 x

EV/CFO

17.7 x

Revenue/Employee

7.2 m
Show all financial metrics
Report incorrect company information